Las Vegas, USA, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight
DelveInsight analyses a robust Alcohol Use Disorder Pipeline with more than 30+ companies involved in the development of novel 30+ Alcohol Use Disorder treatment therapies including names such as Adial Pharmaceuticals, MediciNova, Kinnov therapeutics, Opiant Pharmaceuticals, Marperg, and several others.
DelveInsight’s ‘Alcohol Use Disorder Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Alcohol Use Disorder pipeline domain.
Some of the essential takeaways from the Alcohol Use Disorder Pipeline report:
- DelveInsight’s Alcohol Use Disorder Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.
- Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Alcohol Use Disorder treatment scenario include Adial Pharmaceuticals, R-Pharm Synergy Research, Arbor Pharmaceuticals, Laboratorio Farmaceutico, Gilead Sciences, Kinnov Therapeutics, Opiant Pharmaceuticals, MediciNova, Bioprojet, Corcept Therapeutics, Pfizer, Dicerna Pharmaceuticals, Organon, Confluence Pharmaceuticals, Amygdala Neurosciences, Laboratorio Farmaceutico, Pop Test Oncology, Whanin Pharmaceutical, Astraea Therapeutics, Cybin, BioXcel Therapeutics, Mapreg, Arbutus Biopharma, Merck Sante, Odyssey pharmaceuticals, Dupont, Tonix Pharmaceuticals and many others.
- Essential Alcohol Use Disorder pipeline therapies such as WIL-1903, Nociceptin receptor agonists, CYB003, BXCL501, PT150, DCR-AUD, MAP4343, KT 110, Ibudilast/MN-166, AD04/Ondansetron, ANS-6637, GET73, and others are under development in different phases of clinical trials.
- TKM-ALDH is a very unique application of RNAi being developed by Arbutus Biopharma. TKM-ALDH is designed to knock down or silence the Aldehyde dehydrogenase (ALDH) enzyme to induce long term acute sensitivity to ethanol, for use in severe Alcohol Use Disorder treatment.
- DCR-AUD is Dicerna’s GalXC™ RNAi investigational candidate designed to silence ALDH2 (aldehyde dehydrogenase 2) messenger RNA (mRNA) expression in the liver. In September 2021, Phase I clinical trial to assess DCR-AUD.
- In July 2020, Adial Pharmaceuticals announced that the European Medicines Agency (EMA) has accepted its Pediatric Investigation Plan (PIP) for the development of the Company's lead drug candidate, AD04, for the treatment of Alcohol Use Disorder (AUD) in the pediatric population, ages 12 to 17.
- Chronos Therapeutics is developing CTDP-002, orexin 1 antagonists to target binge eating, alcohol and nicotine addictions.
- Adial pharmaceuticals and Tedor Pharma, full-service contract development and manufacturing organization (CDMO) have entered into a collaboration agreement to provide cGMP contract manufacturing services for AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.
- OPNT002 is a very rapid-acting, intranasal formulation of naltrexone. Phase I clinical data with OPNT002 demonstrated rapid intranasal absorption and a short duration of action compared to currently available products. Opiant plans to initiate a double-blind, placebo-controlled Phase II study in patients diagnosed with Alcohol Use Disorder.
Request a sample and discover more about the report offerings @ Alcohol Use Disorder Emerging Therapies
The Alcohol Use Disorder pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Alcohol Use Disorder products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Alcohol Use Disorder pipeline landscape.
Alcohol Use Disorder also referred to as Alcoholism is the most severe form of alcohol abuse and involves the inability to manage drinking habits. It is also known as Alcohol Addiction. These are common and potentially lethal disorders that mimic and exacerbate a wide range of additional medical and psychiatric conditions, and thereby shorten the lifespans of affected people by more than a decade.
Find out more about the disease and recent developments @ Alcohol Use Disorder Pipeline Assessment
Alcohol Use Disorder Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| WIL-1903 | Whanin Pharmaceutical | Preclinical | NA | Parenteral |
| CYB003 | Cybin | Preclinical | NA | NA |
| BXCL501 | BioXcel Therapeutics | Phase I | Alpha 2 adrenergic receptor agonists | Sublingual |
| PT150 | Pop Test Oncology | Phase I | Glucocorticoid receptor antagonists | Oral |
| DCR-AUD | Dicerna Pharmaceuticals | Phase I | Aldehyde dehydrogenase 2 inhibitors | Subcutaneous |
| MAP4343 | Mapreg | Phase II | Microtubule-associated protein stimulants | Oral |
| KT 110 | Kinnov Therapeutics | Phase II | Alpha 1 adrenergic receptor antagonists | Oral |
| Ibudilast/MN-166 | MediciNova | Phase II | Type 3, 4 cyclic nucleotide phosphodiesterase inhibitors | Oral |
| AD04/Ondansetron | Adial Pharmaceuticals | Phase III | Serotonin 3 receptor antagonists | Oral |
| GET73 | Laboratorio Farmaceutico | Phase II | Metabotropic glutamate receptor 5 antagonists | Oral |
Learn more about the novel and emerging Alcohol Use Disorder medications pipeline @ Alcohol Use Disorder Pipeline Analysis
Alcohol Use Disorder Therapeutics Assessment
The Alcohol Use Disorder Pipeline report proffers an integral view of the Alcohol Use Disorder emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.
By Alcohol Use Disorder Product Type
- Mono
- Combination
- Mono/Combination
By Alcohol Use Disorder Clinical Stages
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Alcohol Use Disorder Therapeutic Route of Administration
- Oral
- Intravenous
- Inhalation
- Subcutaneous
By Alcohol Use Disorder Therapies Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
By Alcohol Use Disorder Therapies Mechanism of Action
- Metabotropic glutamate receptor 5 antagonists
- Serotonin 3 receptor antagonists
- Alpha 1 adrenergic receptor antagonists
- Aldehyde dehydrogenase 2 inhibitor
- Glucocorticoid receptor antagonists
- Opioid receptor antagonists
- Microtubule-associated protein stimulants
Scope of the Alcohol Use Disorder Pipeline Report
- Coverage: Global
- Major Alcohol Use Disorder Players: Adial Pharmaceuticals, R-Pharm Synergy Research, Arbor Pharmaceuticals, Laboratorio Farmaceutico, Gilead Sciences, Kinnov Therapeutics, Opiant Pharmaceuticals, MediciNova, Bioprojet, Corcept Therapeutics, Pfizer, Dicerna Pharmaceuticals, Organon, Confluence Pharmaceuticals, Amygdala Neurosciences, Laboratorio Farmaceutico, Pop Test Oncology, Whanin Pharmaceutical, Astraea Therapeutics, Cybin, BioXcel Therapeutics, Mapreg, Arbutus Biopharma
- Key Alcohol Use Disorder Pipeline Therapies: WIL-1903, Nociceptin receptor agonists, CYB003, BXCL501, PT150, DCR-AUD, MAP4343, KT 110, Ibudilast/MN-166, AD04/Ondansetron, ANS-6637, GET73
Dive deep into rich insights about emerging drugs for Alcohol Use Disorder assessment, visit @ Alcohol Use Disorder Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Alcohol Use Disorder: Overview |
| 4 | Alcohol Use Disorder Pipeline Therapeutics |
| 5 | Alcohol Use Disorder: Late Stage Products (Phase III) |
| 5.1 | AD04: Adial Pharmaceuticals |
| 6 | Alcohol Use Disorder: Mid Stage Products (Phase II) |
| 6.1 | KT 110: Kinnov Therapeutics |
| 7 | Alcohol Use Disorder: Mid Stage Products (Phase II) |
| 7.1 | Ibudilast: MediciNova |
| 8 | Alcohol Use Disorder: Early Stage Products (Phase I) |
| 8.1 | PT150: Pop Test Oncology |
| 9 | Alcohol Use Disorder: Early Stage Products (Phase I) |
| 9.1 | BXCL501: BioXcel Therapeutics |
| 10 | Alcohol Use Disorder: Preclinical Stage Products |
| 11 | Alcohol Use Disorder Therapeutic Assessment |
| 12 | Inactive Products in Alcohol Use Disorder |
| 13 | Collaborations Assessment- Licensing / Partnering / Funding |
| 14 | Alcohol Use Disorder- Unmet Needs |
| 15 | Alcohol Use Disorder- Market Drivers and Barriers |
| 16 | Appendix |
| 17 | About DelveInsight |
For further information on the Alcohol Use Disorder current pipeline therapeutics, reach out @ Alcohol Use Disorder Ongoing Clinical Trials
Track and assess a candidate’s clinical development journey through Actionable Intelligence and Comparative Therapeutic Assessment
Related Reports
DelveInsight’s ‘Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, market trends, market drivers, market barriers, and key companies involved such as Merck Sante, Odyssey pharmaceuticals, Dupont, MediciNova, Adial Pharmaceuticals, Tonix Pharmaceuticals, and others.
Alcohol Use Disorder Epidemiology
DelveInsight’s ‘Alcohol Use Disorder- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Alcohol Use Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight’s ‘Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as DURECT Corporation, Novartis, and many others.
DelveInsight’s, “Alcoholic Hepatitis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key companies involved such as Durect, Novartis, Immuron Ltd, Immunemed, Evive Biotech, Surrozen, Arrowhead Pharmaceuticals, Seal rock therapeutics, and many others.
DelveInsight’s ‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends, market drivers, market barriers, unmet medical needs, SWOT analysis and key companies involved such as Pfizer, GlaxoSmithKline, Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics (NFL Biosciences SAS), Novo Nordisk, and many others.
Smoking Cessation and Nicotine Deaddiction Pipeline
DelveInsight’s, “Smoking Cessation and Nicotine Deaddiction – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key companies involved such as Achieve LifeSciences, NFL Biosciences, Axsome Therapeutics, and others.
DelveInsight’s, “Cocaine Use Disorder - Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Cocaine Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products and key companies involved such as Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics, and others.
Browse Through Our Blog Posts
- Marijuana as a treatment approach
- Alcohol Use Disorder (AUD): When Drinking Becomes A Headache
- The Rising Burden of Substance Use Disorder And The Treatment Scenario
- Gene therapy might make cocaine less addictive
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
